NRG1 and non-small cell lung carcinoma: The RAIN-701 trial is a preclinical model in which tarloxotinib was evaluated in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertions or HER2 activating mutations, as well as those with NRG1, EGFR, HER2, or HER4 gene fusions.